Q-omics provides the consensus-scored GRM7-AS2 profile across patient tissues and cancer cell-line models. GRM7-AS2 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GRM7-AS2 is differentially expressed in 3, with the highest sampling consensus in LUSC. Additionally, GRM7-AS2 RNA expression shows 12,514 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight KIRC, LUSC, and HNSC as cancer lineages where GRM7-AS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GRM7-AS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GRM7-AS2 survival associations across molecular data types. GRM7-AS2 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GRM7-AS2 RNA expression–survival associations across cancer types. High GRM7-AS2 expression shows unfavorable associations in KIRC, LIHC, THCA and CESC, but favorable associations in PAAD and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for GRM7-AS2 RNA expression.
This table summarizes GRM7-AS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for GRM7-AS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GRM7-AS2 shows higher tumor expression in LUSC, COAD and BRCA. The LUSC box plot shows higher GRM7-AS2 RNA expression in tumor versus normal tissue (log2 FC = +0.052, t-test p < 0.001).
This table shows molecular features associated with GRM7-AS2 in patient tissues and cancer cell lines. In patient samples, GRM7-AS2 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set.
